Kura Oncology (KURA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 4, 2026, to be held virtually for shareholders of record as of April 6, 2026.

• Shareholders are encouraged to review proxy materials online and vote using a provided control number.

Voting matters and shareholder proposals

• Election of three Class III directors for three-year terms: Diane Parks, Mary T. Szela, and Michael J. Vasconcelles, M.D.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (Say-on-Pay) and preferred frequency for future Say-on-Pay votes.

• Approval of amendments to the 2014 Equity Incentive Plan and 2015 Employee Stock Purchase Plan.

• Provision to transact other business as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting "FOR" all director nominees and all proposals except for proposal 4, where "1 YEAR" is recommended for Say-on-Pay frequency.